文献速递妇科肿瘤

强化随访对比最简随访方案对子宫内膜癌患者生存的有效性(TOTEM研究):一项随机、实用性、平行组、多中心试验

Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial.
PubMed 文献 · J Clin Oncol · 2022-07-20

TOTEM研究在意大利和法国42家医院纳入1,871例子宫内膜癌术后完全临床缓解、FIGO I-IV期患者,按中心和复发风险分层后1:1随机接受强化(INT)或最简(MIN)随访。中位随访69个月,5年OS为INT组90.6%对比MIN组91.9%(HR 1.13,95%CI 0.86-1.50,P=.380)。结论认为强化随访未改善OS,即使在复发高危患者中也是如此。

要点

  • 5年OS在INT组为90.6%,在MIN组为91.9%(HR 1.13,95%CI 0.86-1.50,P=.380)。
  • 复发检出概率在INT组略高于MIN组(HR 1.17,95%CI 0.92-1.48,P=.194)。
  • 作者认为无需在试验所用MIN方案中常规加入阴道细胞学、实验室或影像检查。

核心结论

  • 在子宫内膜癌术后患者中,强化随访方案未改善OS,即使在复发高危患者中也是如此。
  • 作者认为:根据现有证据,无需在试验所用MIN方案中常规加入阴道细胞学、实验室或影像检查。

研究设计与样本

  • TOTEM研究为大型、实用性、随机、平行组、多中心试验,在意大利和法国的42家医院开展。
  • 纳入对象为子宫内膜癌手术后、完全临床缓解、FIGO I-IV期患者(n=1,871,2008年11月至2018年7月随机分组)。
  • 按中心和复发风险(低或高)分层后按1:1随机分配至INT或MIN的在院随访方案。
  • 研究把握度为证明INT方案使5年OS绝对改善5%。
  • 最终分析可评估1,847例(98.7%),其中60%为低危。

主要发现

  • 中位随访69个月。
  • 5年OS在INT组为90.6%,在MIN组为91.9%(HR 1.13,95%CI 0.86-1.50,P=.380)。
  • 按年龄、癌症治疗、复发风险、中心对计划随访依从程度的亚组分析均未发现OS差异。
  • 复发检出概率在INT组略高于MIN组(HR 1.17,95%CI 0.92-1.48,P=.194)。

临床怎么用

  • 作者认为,根据现有证据,无需在试验所用MIN方案中常规加入阴道细胞学、实验室或影像检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In the absence of clear evidence from randomized trials, the intensity of follow-up regimens after surgical treatment of endometrial cancer is highly variable in clinical practice. To reduce this uncertainty, we conducted a randomized trial to test whether an intensive (INT) versus a minimalist (MIN) follow-up regimen improves overall survival (OS) in patients undergoing operation for endometrial cancer. METHODS: The TOTEM study was a large, pragmatic randomized trial, conducted in 42 hospitals (in Italy and France) including patients surgically treated for endometrial cancer, in complete clinical remission, International Federation of Gynecology and Obstetrics stage I-IV. After stratification by center and risk of relapse (low or high), patients were randomly assigned (1:1) to INT or MIN hospital-based follow-up regimens. The study was powered to demonstrate an absolute improvement of 5% of the 5-year OS with the INT regimen. RESULTS: In total, 1,871 patients were randomly assigned between November 2008 and July 2018, and 1,847 patients (98.7%) were available for the final analysis (60% low risk). After a median follow-up of 69 months, the 5-year OS was 90.6% in the INT and 91.9% in the MIN arms (hazard ratio, 1.13, 95% CI, 0.86 to 1.50, P = .380). No differences in OS were found in subgroup analyses considering age, cancer treatment, risk of relapse, and degree of adherence of the center to the scheduled follow-up. The probability of detecting a relapse was slightly higher in the INT arm (hazard ratio, 1.17; 95% CI, 0.92 to 1.48; P = .194). CONCLUSION: An INT follow-up in endometrial cancer-treated patients does not improve OS, even in high-risk patients. According to available evidence, there is no need to routinely add vaginal cytology, laboratory, or imaging investigations to the MIN regimens used in this trial.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zola P, Ciccone G, Piovano E, et al. Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients With Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial. J Clin Oncol. 2022. PMID: 35858170. doi:10.1200/JCO.22.00471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。